151. Streamlined detection of Nipah virus antibodies using a split NanoLuc biosensor
- Author
-
Éric Bergeron, Cheng-Feng Chiang, Michael K. Lo, Elif Karaaslan, Syed Moinuddin Satter, Mohammed Ziaur Rahman, Mohammad Enayet Hossain, Wasik Rahman Aquib, Dewan Imtiaz Rahman, Subyeta Binte Sarwar, Joel M. Montgomery, John D. Klena, and Christina F. Spiropoulou
- Subjects
Nipah virus ,serology ,disease surveillance ,antibodies ,paramyxoviridae ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Nipah virus (NiV) is an emerging zoonotic RNA virus that can cause fatal respiratory and neurological diseases in animals and humans. Accurate NiV diagnostics and surveillance tools are crucial for the identification of acute and resolved infections and to improve our understanding of NiV transmission and circulation. Here, we have developed and validated a split NanoLuc luciferase NiV glycoprotein (G) biosensor for detecting antibodies in clinical and animal samples. This assay is performed by simply mixing reagents and measuring luminescence, which depends on the complementation of the split NanoLuc luciferase G biosensor following its binding to antibodies. This anti-NiV-G “mix-and-read” assay was validated using the WHO's first international standard for anti-NiV antibodies and more than 700 serum samples from the NiV-endemic country of Bangladesh. Anti-NiV antibodies from survivors persisted for at least 8 years according to both ⍺NiV-G mix-and-read and NiV neutralization assays. The ⍺NiV-G mix-and-read assay sensitivity (98.6%) and specificity (100%) were comparable to anti-NiV IgG ELISA performance but failed to detect anti-NiV antibodies in samples collected less than a week following the appearance of symptoms. Overall, the anti-NiV-G biosensor represents a simple, fast, and reliable tool that could support the expansion of NiV surveillance and retrospective outbreak investigations.
- Published
- 2024
- Full Text
- View/download PDF